Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTO)
NASDAQ:APTO
Total Valuation
Aptose Biosciences has a market cap or net worth of $8.14M. The enterprise value is $25.21M.
Market Cap$8.14M
Enterprise Value$25.21M
Share Statistics
Aptose Biosciences has 2,552,429 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,552,429
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aptose Biosciences’s return on equity (ROE) is 17.65 and return on invested capital (ROIC) is 2776.03%.
Return on Equity (ROE)17.65
Return on Assets (ROA)-3.94
Return on Invested Capital (ROIC)2776.03%
Return on Capital Employed (ROCE)22.96
Revenue Per Employee0.00
Profits Per Employee-1.46M
Employee Count35
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aptose Biosciences is -0.33. Aptose Biosciences’s PEG ratio is >-0.01.
PE Ratio-0.33
PS Ratio―
PB Ratio-5.83
Price to Fair Value-5.83
Price to FCF-0.38
Price to Operating Cash Flow-0.38
PEG Ratio>-0.01
Income Statement
In the last 12 months, Aptose Biosciences had revenue of 0.00 and earned -51.21M in profits. Earnings per share was -7.58.
Revenue0.00
Gross Profit0.00
Operating Income-52.36M
Pretax Income-51.21M
Net Income-51.21M
EBITDA-52.27M
Earnings Per Share (EPS)-7.58
Cash Flow
In the last 12 months, operating cash flow was -37.18M and capital expenditures 0.00, giving a free cash flow of -37.18M billion.
Operating Cash Flow-37.18M
Free Cash Flow-37.18M
Free Cash Flow per Share-14.56
Dividends & Yields
Aptose Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.25
52-Week Price Change-93.90%
50-Day Moving Average3.99
200-Day Moving Average9.89
Relative Strength Index (RSI)26.12
Average Volume (3m)266.34K
Important Dates
Aptose Biosciences upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateMar 28, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Aptose Biosciences as a current ratio of 0.78, with Debt / Equity ratio of -117.37%
Current Ratio0.78
Quick Ratio0.78
Debt to Market Cap0.00
Net Debt to EBITDA0.16
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aptose Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aptose Biosciences EV to EBITDA ratio is -0.17, with an EV/FCF ratio of -0.19.
EV to Sales0.00
EV to EBITDA-0.17
EV to Free Cash Flow-0.19
EV to Operating Cash Flow-0.19
Balance Sheet
Aptose Biosciences has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.72M billion.
Cash & Marketable Securities$0.00
Total Debt$0.00
Net Cash$10.72M
Net Cash Per Share$4.20
Tangible Book Value Per Share-$0.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aptose Biosciences is $9.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.25
Price Target Upside360.20% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―